Symptoms of Myasthenia Gravis Diagnosis of Myasthenia Gravis Myasthenia Gravis Treatment Options
Understanding Myasthenia Gravis: Symptoms, Diagnosis, and Treatment Options Read More »
England could lose 16,000 GPs.
England could lose 16,000 GPs Read More »
FDA warns consumers about fraudulent Ebola treatment products via FDA warns consumers about fraudulent Ebola treatment products. The U.S. Food and Drug Administration is advising consumers to be aware of products sold online claiming to prevent or treat the Ebola virus. Since the outbreak of the Ebola virus in West Africa, the FDA has seen
FDA warns consumers about fraudulent Ebola treatment products Read More »
Chemical in coffee may help prevent obesity-related disease Friday, 14 November 2014 Researchers at the University of Georgia have discovered that a chemical compound commonly found in coffee may help prevent some of the damaging effects of obesity. In a paper published recently in Pharmaceutical Research, scientists found that chlorogenic acid, or CGA, significantly reduced
Coffee may help effects of obesity Read More »
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque auctor aliquam lectus eget venenatis. Nam fermentum est quam, sit amet porttitor quam blandit nec. Morbi condimentum felis felis, in auctor sapien commodo ac. Donec eget felis arcu. Maecenas sit amet sapien vel eros commodo dictum. Aenean arcu orci, placerat ac consequat eget, facilisis et arcu.
European Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application for Asfotase Alfa as a Treatment for Patients with HypophosphatasiaEuropean Medicines Agency Accepts Marketing Authorization Application
European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan Drug Designation to Soliris® (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)European Commission Grants Orphan
